The Global Prevalence of <i>Strongyloides stercoralis</i> Infection.

Buonfrate D, Bisanzio D, Giorli G, Odermatt P, Fürst T, Greenaway C, French M, Reithinger R, Gobbi F, Montresor A, Bisoffi Z. · 2020

Read The Global Prevalence of <i>Strongyloides stercoralis</i> Infection. by Buonfrate D, Bisanzio D, Giorli G, Odermatt P, Fürst T, Greenaway C, French M, Reithinger R, Gobbi F, Montresor A, Bisoffi Z. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7349647.txt.

Introduction

Buonfrate and co-authors present a prevalence study in Pathogens on a worm infection. The parasite is Strongyloides stercoralis, a neglected tropical disease threat. Older global counts ranged widely and rested on weak tests. The team set out to give a firmer world estimate.

The authors reviewed prevalence studies from 1990 to 2016 across endemic countries. They adjusted each result for the test used and for age. A statistical model then filled gaps for countries with no data. They estimate a global prevalence of about 8 percent for 2017. That equals roughly 614 million people infected. South-East Asia, Africa, and the Western Pacific held most cases. Readers get country-level numbers to guide mass drug campaigns.

Catalog record

CREATORBuonfrate D, Bisanzio D, Giorli G, Odermatt P, Fürst T, Greenaway C, French M, Reithinger R, Gobbi F, Montresor A, Bisoffi Z.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7349647

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The Global Prevalence of Strongyloides stercoralis Infection By Dora Buonfrate, Donal Bisanzio, Giovanni Giorli, Peter Odermatt, Thomas Fürst, Christina Greenaway, Michael French, Richard Reithinger, Federico Gobbi, Antonio Montresor, Zeno Bisoffi Published in: Pathogens DOI: 10.3390/pathogens9060468 ABSTRACT Abstract Strongyloidiasis is a common neglected tropical disease in tropical and sub-tropical climatic zones. At the worldwide level, there is high uncertainty about the strongyloidiasis burden. This uncertainty represents an important knowledge gap since it affects the planning of interventions to reduce the burden of strongyloidiasis in endemic countries. This study aimed to estimate the global strongyloidiasis prevalence. A literature review was performed to obtain prevalence data from endemic countries at a worldwide level from 1990 to 2016. For each study, the true population prevalence was calculated by accounting for the specificity and the sensitivity of testing and age of tested individuals. Prediction of strongyloidiasis prevalence for each country was performed using a spatiotemporal statistical modeling approach. The country prevalence obtained from the model was used to estimate the number of infected people per country. We estimate the global prevalence of strongyloidiasis in 2017 to be 8.1% (95% CI: 4.2–12.4%), corresponding to 613.9 (95% CI: 313.1–910.1) million people infected. The South-East Asia, African, and Western Pacific Regions accounted for 76.1% of the global infections. Our results could be used to identify those countries in which strongyloidiasis prevalence is highest and where mass drug administration (MDA) should be deployed for its prevention and control. Keywords: strongyloides, strongyloidiasis, prevalence, epidemiology 1. INTRODUCTION Strongyloidiasis is the infection caused by the soil-transmitted helminth (STH) Strongyloides stercoralis. Its global prevalence was previously estimated at 30–100 million infected people [1], but these estimates were subsequently questioned in light of diagnostic issues that characterized the few studies available at that time [2]. Moreover, neither the source nor the methods which formed the basis for these estimates were reported in the paper. Indeed, the diagnostic methods commonly used in the field for other STHs, such as Kato–Katz and direct smear examination, have a very low sensitivity for S. stercoralis [3]. The Baermann method and Koga agar plate culture (APC) have a higher sensitivity than stool microcopy, but still miss a large proportion of infections [3]; polymerase chain reaction (PCR) is highly specific, but not more sensitive than the Baermann method and APC [4]. Serology is the most sensitive method, although false positive results are possible, due to cross-reactions and long-term persistence of antibodies [3]. Overall, none of the available diagnostic tests can be considered the gold standard for the diagnosis of strongyloidiasis. Recently, a paper estimated the prevalence of strongyloidiasis as a ratio to hookworm, in order to partly overcome the diagnostic issue [5]. The morbidity caused by S. stercoralis is not well defined compared to other STHs. A systematic review evaluated the clinical burden caused by strongyloidiasis and reported that urticaria (reported by 33% of infected individuals in the included studies), abdominal pain (62%), and diarrhea (50%) might be frequently affecting people with strongyloidiasis [6]. Although the results of the review were limited by the paucity of studies focusing on this topic, the clinical relevance of S. stercoralis infection cannot be disregarded, because in immunosuppressed individuals it can lead to a syndrome (hyperinfection/dissemination) that is invariably fatal if not promptly and properly cured and is often fatal despite treatment [7]. Ivermectin (IVM) is the drug of choice for the treatment of S. stercoralis infection [7], and it has been recently included in the WHO list of essential medicines for this purpose [8]. Unfortunately, IVM is often not easily available outside specific donation programs aimed at the elimination of lymphatic filariasis (LF) and onchocerciasis. Currently, no specific strategies for the control of S. stercoralis infection have been implemented in endemic areas. This is mostly due to the knowledge gap regarding the global prevalence of the disease and the difficult access to quality-assured and affordable IVM. In this work, we aimed to estimate the prevalence of strongyloidiasis at a global and country level, using a spatiotemporal statistical modeling approach. 2. RESULTS 2.1. Review of the Literature The flow of the literature review is described in Figure 1. The review of the literature identified 146 articles (Supplementary File S1) with data on the prevalence of strongyloidiasis from 43 countries (Figure 2). Brazil and Thailand were the countries with the highest number of studies. Twenty studies used either the Baermann method or stool culture (including agar plate, Harada Mori or any other cultural method) as diagnostic methods; a combination of diagnostic tests including Baermann method and/or stool culture was used in 22 studies. PCR was used in 7 studies, and a further 2 studies used it in combination with other tests. Serology was used in 16 studies, and a further 3 studies used serology in combination with other tests. The remaining studies used less sensitive diagnostic methods (mostly Kato–Katz and single/multiple direct smears). The prevalence reported was adjusted considering the diagnostic test used, as described above in the Methods section. [Figure: Flow chart describing the review process.] [Figure: Year of survey reported in the research publications included in the literature review by country. In the Y-axis, country codes are reported according to ISO 3 (legend available in Table S2).] 2.2. Global and Regional (WHO) Prevalence According to the Model The best model describing strongyloidiasis prevalence included GDP, percentage of rural population, territory roughness, sanitation, annual mean temperature, and annual precipitation: [formula: (1)STG-PR = GDP + RURAL + RUG + SANIT + TEMP + RAIN + REGIONRND] This model was used to estimate strongyloidiasis prevalence for each country at the worldwide level with a 95% confidence interval (95% CI). Strongyloidiasis prevalence and number of infected people are reported at the world and regional levels in Table 1 and Figure 3. [Table: Global and regional S. stercoralis prevalence (STG-PR), the number of infected individuals.] [Figure: Estimated strongyloidiasis prevalence (STG-PR) for 2017, as predicted by the best statistical model.] In 2017, the estimated strongyloidiasis prevalence was 8.1% (95% CI: 4.2%–12.4%), which corresponds to 613.9 (95% CI: 313.1–910.1) million people infected with Strongyloides. Referring to the WHO regions, the highest number of infected people live in the South-East Asia Region (SEAR) estimated at 237.3 (95% CI: 129.9–353.3) million, followed by Western Pacific Region (WPR) with 133.2 (95% CI: 68.1–198.4) million, and African Region (AFR) with 108.1 (95% CI: 55.1–160.9) million; combined this represents 76.1% of the total infected population worldwide (Table 1). At the regional level, high S. stercoralis prevalence was estimated for countries in AFR (10.3%; 95% CI: 5.3–15.3%), for the Americas Region (AMR) (6.9%; 95% CI: 3.5–10.2%), and SEAR (12.1%; 95% C.I.: 6.1–17.9%). In the AMR, countries in Central America and the northern part of South America had the highest prevalence (Figure 3), particularly Panama (15.7%; 95% CI: 8–23.4%), Costa Rica (15.7%; 95% CI: 8–23.4%), and Colombia (18.4%; 95% CI: 9.4–27.4%). S. stercoralis prevalence in AFR was estimated to be high in sub-Saharan countries, with prevalence in West Africa higher compared with the rest of the AFR countries and Sierra Leone (17%; 95% CI: 8.7–25.3%), Liberia (16%; 95% CI: 8.4–24.6%), and Sao Tome and Principe (20.7%; 95% CI: 10.6–30.8%) having particularly high estimated prevalence. All countries in the SEAR had high levels of strongyloidiasis prevalence, with the

Read the complete text